Clik here to view.
Presumption Compensability in Workers’ Comp: A Proactive Approach
Tammy Odierna, Regulatory Data Analyst With every tragedy, there is insight. The diagnosis of cancer among emergency personnel years after the 9-11 tragedy has provoked workers’ compensation...
View ArticleClik here to view.
Drug of the month for June: 5 Points to Remember When Considering Amrix
By: Alan O. Rook, PharmD. myMatrixx Clinical Pharmacist This is the third post for our “Drug of the Month” blog. The medication that we’re highlighting is Amrix® (cyclobenzaprine extended-release)....
View ArticleClik here to view.
What Does the New NSAID Label Warning Mean for Workers’ Comp?
By Sam Aminov, PharmD, MBA FDA Strengthens Label Warning on NSAIDs In a recent Drug Safety Communication, the U.S. Food and Drug Administration (FDA) strengthened an existing label warning that...
View ArticleClik here to view.
Balancing the Risks & Benefits of Pain Management: NSAIDs vs. Opioids and...
By Sam Aminov, PharmD, MBA Last week’s post about the updated FDA warning labels for NSAID products prompted some thought for appropriate treatment strategies for injured workers as it relates to acute...
View ArticleStates Continue to Take a Stand Against the Prescription Opioid Epidemic
By Tammy Odierna, Regulatory Data Analyst, myMatrixx Earlier this month, Connecticut Governor Dannel Malloy hosted a bill signing ceremony to celebrate passage of PDMP legislation: CT HB 6856. Governor...
View ArticleClik here to view.
Drug of the Month: 4 Things You Should Know About Amitiza
By: Ashton Hamilton, PharmD candidate Alan Rook, PharmD 1. What is Amitiza®? Amitiza (lubiprostone), manufactured by Takeda Pharmaceuticals Inc., is FDA approved for opioid-induced constipation in...
View ArticleClik here to view.
Drug of the Month: 4 Key Things to Know About Lyrica®
By: Ashton Hamilton, PharmD candidate and Alan Rook, PharmD 1. What is Lyrica? Lyrica® (pregabalin) is FDA approved for fibromyalgia, diabetic peripheral neuropathic pain, neuropathic pain associated...
View ArticleCalifornia Formulary News
Legislation mandating a formulary, AB 1124, has been approved by the California legislature and has been sent to Governor Jerry Brown (D). AB 1124 provides the framework for the Division of Workers’...
View ArticleClik here to view.
Drug of the Month: Relistor® A Step-Therapy Approach to Opioid-Induced...
By: Rachel Crowe, PharmD Candidate 2016 Alan Rook, PharmD 1. What is Relistor®? Relistor® (methylnaltrexone bromide), manufactured by Valeant Pharmaceuticals International, Inc., is FDA approved for...
View ArticleNew “N” Drug Classifications in Texas and Oklahoma: Essential Information for...
by Phil Walls, myMatrixx Chief Clinical Officer The Texas Department of Insurance Division of Workers’ Compensation has announced that both Duragesic® (fentanyl) transdermal system patches and MS...
View ArticleUncontrolled and Arbitrary Drug Inflation
By Lisa Luong, PharmD and Michael Nguyen, PharmD When Turing Pharmaceuticals acquired Daraprim® (pyrimethamine), a well-established treatment for toxoplasmosis, Turing’s CEO Martin Shkreli made a...
View ArticleGet Ahead of the Claim: Watch Out for PPIs
By Phil Walls, RPh Chief Clinical Officer, myMatrixx Proton Pump Inhibitors or PPIs are in a category of drugs we are very familiar with in workers’ compensation because they are commonly used to treat...
View ArticleClik here to view.
2016 CDC Opioid Prescribing Guidelines: A Summary of Key Points
by Lindsey Marshall, PharmD candidate and Alan Rook, PharmD The Centers for Disease Control and Prevention (CDC) continuously updates their databases to provide the most current information for...
View ArticleJourney to a Guideline: The Process and Overview of the Long-Awaited CDC...
by Phil Walls, RPh, myMatrixx Chief Clinical Officer and Steven Stanos, DO, myMatrixx Medical Director Will the New CDC Guideline Have an Impact on Opioid Prescribing? Last week, myMatrixx released a...
View ArticleClik here to view.
Key Points from President Obama and Other Leaders’ Messages at the National...
By Phil Walls, RPh Chief Clinical Officer, myMatrixx I had the unique opportunity to hear the president of the United States and other key leaders speak on the problem of drug abuse this week....
View ArticleDrug of the Month – Vivlodex™ (meloxicam)
By: Krupa Patel, PharmD candidate 2016 and Alan Rook, PharmD What is Vivlodex™? Vivlodex (meloxicam) is a single-source brand medication that was FDA approved in October 2015 for the management of...
View ArticlePDMP Changes in Maine Provide Improvements
On 4/19/16 Maine Senate Bill 671 entitled “An Act To Prevent Opiate Abuse by Strengthening the Controlled Substances Prescription Monitoring Program” was signed into law by the governor. The new law...
View ArticleClik here to view.
Drug of the Month: 4 Key Things to Know About Lyrica®
By: Ashton Hamilton, PharmD candidate and Alan Rook, PharmD 1. What is Lyrica? Lyrica® (pregabalin) is FDA approved for fibromyalgia, diabetic peripheral neuropathic pain, neuropathic pain associated...
View ArticleClik here to view.
Buyer Beware!
By Michael Nguyen, PharmD and Phil Walls, RPh PatchWerx Alert If you haven’t heard of PatchWerx yet, please be on the alert for the following products from this manufacturer: In this age of life-saving...
View ArticleClik here to view.
Drug Dealers Are No Longer the Main Source of the Most Frequently Abused Drugs
By Andi Moore, PharmD myMatrixx VP of Clinical Strategy The abuse of opioids, resulting in addiction and death, is an urgent public health concern in the US. This topic has drawn much media attention...
View Article
